Compare KRYS & HSIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRYS | HSIC |
|---|---|---|
| Founded | 2015 | 1932 |
| Country | United States | United States |
| Employees | 295 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.3B | 8.7B |
| IPO Year | 2017 | 1996 |
| Metric | KRYS | HSIC |
|---|---|---|
| Price | $340.21 | $80.10 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 16 |
| Target Price | ★ $297.60 | $85.07 |
| AVG Volume (30 Days) | 294.7K | ★ 1.3M |
| Earning Date | 05-04-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 128.00 | 7.21 |
| EPS | ★ 1.83 | 0.92 |
| Revenue | $389,130,000.00 | ★ $13,201,995,000.00 |
| Revenue This Year | $38.74 | $6.12 |
| Revenue Next Year | $32.53 | $3.64 |
| P/E Ratio | $187.67 | ★ $85.51 |
| Revenue Growth | ★ 33.94 | 5.94 |
| 52 Week Low | $130.50 | $61.97 |
| 52 Week High | $356.50 | $89.29 |
| Indicator | KRYS | HSIC |
|---|---|---|
| Relative Strength Index (RSI) | 65.25 | 60.70 |
| Support Level | $253.89 | $75.18 |
| Resistance Level | N/A | $80.37 |
| Average True Range (ATR) | 12.77 | 1.77 |
| MACD | 2.68 | 0.04 |
| Stochastic Oscillator | 72.67 | 67.39 |
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
Henry Schein Inc is a solutions company for healthcare professionals. It offers healthcare equipment, products, and services to office-based dental and medical practitioners, as well as alternative sites of care. The company's reportable segments are: Global Distribution and Value-Added Services, Global Specialty Products, and Global Technology. It generates maximum revenue from the Global Distribution and Value-Added Services segment, which includes distribution to the dental and medical markets of national brand and corporate brand merchandise, as well as equipment and related technical services. This segment also includes value-added services such as financial services, continuing education services, consulting, and other practice services.